InvestorsHub Logo
Followers 17
Posts 735
Boards Moderated 0
Alias Born 02/05/2004

Re: None

Saturday, 06/28/2014 2:18:53 PM

Saturday, June 28, 2014 2:18:53 PM

Post# of 346654
3 Biotech Companies That Could Be the Next Intercept or InterMune

"If successful, bavituximab could revolutionize the second-line treatment for NSCLC, and it may hold promise as a first-line treatment, too."

http://www.barchart.com/headlines/story/3600784/3-biotech-companies-that-could-be-the-next-intercept-or-intermune
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News